A novel approach to synaptic protection in Alzheimer’s disease

Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference

PITTSBURGH, Feb. 12, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will be hosting one-on-one meetings at the Leerink Partners 7th Annual Global Healthcare Conference at the Lotte New York Palace Hotel in New York, NY on Wednesday, February 14th and Thursday, February 15th, 2018.

Mr. Moch will be meeting with select institutional investors to provide an overview of the company´s strategy as well as an update on its development program for Elayta™ (CT1812), including three clinical studies which Cognition expects to initiate during the first half of 2018.

About Elayta (CT1812)
Cognition’s lead product candidate, Elayta (CT1812), is a highly brain penetrant small molecule that utilizes a novel synaptoprotective mechanism of action to address the underlying problem of synaptic loss in Alzheimer’s disease. This orally dosed molecule, which has been granted Fast Track designation by the U.S. FDA, displaces toxic beta amyloid (A?) oligomers from their synaptic receptors indirectly by allosterically destabilizing the proximate sigma-2 receptor complex, thereby preventing oligomer binding and protecting synaptic function. Elayta has been shown in a preclinical model of Alzheimer’s disease to stop memory loss and to normalize dysregulated proteins. The results of a Phase 1b/2 clinical study of Elayta in patients with mild-to-moderate Alzheimer’s disease, including the impact of Elayta on biomarkers of synaptic damage, were reported in two late-breaker presentations at the Clinical Trials on Alzheimer’s disease (CTAD) meeting in November 2017.

About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, Elayta, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. Elayta and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.